| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents at beginning of period | NaN | 10,792,172 | 1,037,320 | NaN |
| Gain on loan forgiveness | NaN | NaN | 0 | 0 |
| Net loss | -4,218,332 | -2,247,669 | -2,228,358 | -4,957,165 |
| Depreciation and amortization | 25,872 | 25,460 | 25,868 | 93,405 |
| Share-based compensation | 484,853 | 399,862 | 404,425 | 325,217 |
| Accounts and other receivable | -211,345 | -217,387 | 359,828 | 18,159 |
| Prepaid expenses and other current assets | -36,124 | 155,922 | -34,477 | -73,355 |
| Accounts payable and accrued liabilities | 1,443,516 | -326,452 | 402,422 | -1,117,921 |
| Net cash used in operating activities | -2,016,622 | -2,087,334 | -1,720,994 | -5,601,268 |
| Repayment of debt | NaN | NaN | 0 | 0 |
| Proceeds from issuance of common shares | 0 | 3,497,825 | 220,501 | 7,497,133 |
| Proceeds from issuance of series a-1 preferred shares and warrants | 0 | 0 | 0 | 1,540,820 |
| Proceeds from issuance of series b-1 preferred shares-Series B1Preferred Stock | 0 | NaN | 0 | 8,340,000 |
| Payments for issuance costs of common shares-Common Stock And Warrants | 8,980 | 142,406 | 34,018 | 294,935 |
| Payments for issuance costs of common shares-Preferred Stock | 0 | NaN | 0 | 215,157 |
| Payment for issuance costs of warrants | 0 | NaN | 0 | 23,446 |
| Net cash provided by financing activities | -8,980 | 3,355,419 | 186,483 | 16,844,415 |
| Effect of exchange rate changes on cash and cash equivalents | -22,463 | -8,509 | -35,007 | 81,223 |
| Net change in cash and cash equivalents | -2,048,065 | 1,259,576 | -1,569,518 | 11,324,370 |
| Cash and cash equivalents, beginning of the period | 12,051,748 | NaN | NaN | NaN |
| Cash and cash equivalents at end of period | NaN | 12,051,748 | 10,792,172 | NaN |
| Cash and cash equivalents, end of the period | 10,003,683 | NaN | NaN | NaN |
Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. (EDSA)